ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Structural Determinants of Opioid and NOP Receptor Activity in Derivatives of Buprenorphine

View Author Information
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
SRI International, Menlo Park, California 94025, United States
Tel: 44 (0)1225 383103. Fax: 44 (0)1225 386114. E-mail: [email protected]
Cite this: J. Med. Chem. 2011, 54, 19, 6531–6537
Publication Date (Web):August 25, 2011
https://doi.org/10.1021/jm2003238
Copyright © 2011 American Chemical Society

    Article Views

    1882

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options
    Supporting Info (1)»

    Abstract

    Abstract Image

    The unique pharmacological profile of buprenorphine has led to its considerable success as an analgesic and as a treatment agent for drug abuse. Activation of nociceptin/orphanin FQ peptide (NOP) receptors has been postulated to account for certain aspects of buprenorphine’s behavioral profile. In order to investigate the role of NOP activation further, a series of buprenorphine analogues has been synthesized with the aim of increasing affinity for the NOP receptor. Binding and functional assay data on these new compounds indicate that the area around C20 in the orvinols is key to NOP receptor activity, with several compounds displaying higher affinity than buprenorphine. One compound, 1b, was found to be a mu opioid receptor partial agonist of comparable efficacy to buprenorphine but with higher efficacy at NOP receptors.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    ARTICLE SECTIONS
    Jump To

    Full experimental details (spectra and microanalysis data) plus figures detailing antagonist activity of 6b in vitro. This material is available free of charge via the Internet at http://pubs.acs.org.

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Cited By

    This article is cited by 37 publications.

    1. Linghui Kong, Xuelian Shu, Siyuan Tang, Rongrong Ye, Huijiao Sun, Shuang Jiang, Zixiang Li, Jingrui Chai, Yun Fang, Yinjie Lan, Linqian Yu, Qiong Xie, Wei Fu, Yujun Wang, Wei Li, Zhuibai Qiu, Jinggen Liu, Liming Shao. SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. Journal of Medicinal Chemistry 2022, 65 (15) , 10377-10392. https://doi.org/10.1021/acs.jmedchem.2c00014
    2. James Brailey-Partridge, John S. Carey, Christopher J. Lovell, George M. Taylor. Synthesis of 1-Chloronaloxone and 2-Chloronaloxone. Organic Process Research & Development 2021, 25 (11) , 2502-2507. https://doi.org/10.1021/acs.oprd.1c00288
    3. Qian He, Yuanyuan Wei, Xiao Liu, Rongrong Ye, Linghui Kong, Zixiang Li, Shuang Jiang, Linqian Yu, Jingrui Chai, Qiong Xie, Wei Fu, Yujun Wang, Wei Li, Zhuibai Qiu, Jinggen Liu, Liming Shao. Discovery of an M-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile. Journal of Medicinal Chemistry 2021, 64 (16) , 12414-12433. https://doi.org/10.1021/acs.jmedchem.1c01082
    4. Ariful Islam, Mohammad Atiqur Rahman, Megan B. Brenner, Allamar Moore, Alyssa Kellmyer, Harley M. Buechler, Frank DiGiorgio, Vincent R. Verchio, Laura McCracken, Mousumi Sumi, Robert Hartley, Joseph R. Lizza, Gustavo Moura-Letts, Bradford D. Fischer, Thomas M. Keck. Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA. ACS Pharmacology & Translational Science 2020, 3 (5) , 907-920. https://doi.org/10.1021/acsptsci.0c00066
    5. Li Xiao, Yujun Wang, Mumei Zhang, Weiwei Wu, Linghui Kong, Yan Ma, Xuejun Xu, Xiao Liu, Qian He, Yuanyuan Qian, Huijiao Sun, Haihao Wu, Cheng Lin, Huoming Huang, Rongrong Ye, Shuang Jiang, Ru-Feng Ye, Congmin Yuan, Shengyang Fang, Dengqi Xue, Xicheng Yang, Hao Chen, Yilin Zheng, Linqian Yu, Qiong Xie, Lan Zheng, Wei Fu, Wei Li, Zhuibai Qiu, Jinggen Liu, Liming Shao. Discovery of a Highly Selective and Potent κ Opioid Receptor Agonist from N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaines with Reduced Central Nervous System (CNS) Side Effects Navigated by the Message–Address Concept. Journal of Medicinal Chemistry 2019, 62 (24) , 11054-11070. https://doi.org/10.1021/acs.jmedchem.9b00857
    6. Karel Guillemyn, Joanna Starnowska, Camille Lagard, Jolanta Dyniewicz, Ewelina Rojewska, Joanna Mika, Nga N. Chung, Valérie Utard, Piotr Kosson, Andrzej W. Lipkowski, Lucie Chevillard, Pol Arranz-Gibert, Meritxell Teixidó, Bruno Megarbane, Dirk Tourwé, Frédéric Simonin, Barbara Przewlocka, Peter W. Schiller, and Steven Ballet . Bifunctional Peptide-Based Opioid Agonist–Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. Journal of Medicinal Chemistry 2016, 59 (8) , 3777-3792. https://doi.org/10.1021/acs.jmedchem.5b01976
    7. Juan Pablo Cueva, Christopher Roche, Mehrnoosh Ostovar, Vinod Kumar, Mary J. Clark, Todd M. Hillhouse, John W. Lewis, John R. Traynor, and Stephen M. Husbands . C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors. Journal of Medicinal Chemistry 2015, 58 (10) , 4242-4249. https://doi.org/10.1021/acs.jmedchem.5b00130
    8. Vinod Kumar, Irna E. Ridzwan, Konstantinos Grivas, John W. Lewis, Mary J. Clark, Claire Meurice, Corina Jimenez-Gomez, Irina Pogozheva, Henry Mosberg, John R. Traynor, and Stephen M. Husbands . Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity. Journal of Medicinal Chemistry 2014, 57 (10) , 4049-4057. https://doi.org/10.1021/jm401964y
    9. Ann P. Lin and Mei-Chuan Ko . The Therapeutic Potential of Nociceptin/Orphanin FQ Receptor Agonists as Analgesics without Abuse Liability. ACS Chemical Neuroscience 2013, 4 (2) , 214-224. https://doi.org/10.1021/cn300124f
    10. Stephen M. Husbands . Buprenorphine and Related Orvinols. 2013, 127-144. https://doi.org/10.1021/bk-2013-1131.ch007
    11. Nurulain T. Zaveri Dennis Yasuda Blair V. Journigan Pankaj R. Daga Faming Jiang Cris Olsen . Structure-Activity Relationships of Nociceptin Receptor (NOP) Ligands and the Design of Bifunctional NOP/Mu Opioid Receptor-Targeted Ligands. 2013, 145-160. https://doi.org/10.1021/bk-2013-1131.ch008
    12. Kyle J. Rehrauer, Christopher W. Cunningham. IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics. Pharmacological Research 2023, 197 , 106966. https://doi.org/10.1016/j.phrs.2023.106966
    13. Amélie Soyer, Sarah Leterrier, Louise Breuil, Maud Goislard, Claire Leroy, Wadad Saba, Karine Thibault, Gregory Dal Bo, Michel Bottlaender, Fabien Caillé, Sébastien Goutal, Nicolas Tournier. Validation of a pharmacological imaging challenge using 11C-buprenorphine and 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography to study the effects of buprenorphine to the rat brain. Frontiers in Neuroscience 2023, 17 https://doi.org/10.3389/fnins.2023.1181786
    14. Flaminia Coluzzi, Laura Rullo, Maria Sole Scerpa, Loredana Maria Losapio, Monica Rocco, Domenico Billeci, Sanzio Candeletti, Patrizia Romualdi. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 2022, 36 (6) , 617-632. https://doi.org/10.1007/s40263-022-00924-2
    15. János Marton, Anikó Fekete, Paul Cumming, Sándor Hosztafi, Pál Mikecz, Gjermund Henriksen. Diels–Alder Adducts of Morphinan-6,8-Dienes and Their Transformations. Molecules 2022, 27 (9) , 2863. https://doi.org/10.3390/molecules27092863
    16. Jennifer M. Bossert, E. Andrew Townsend, Lindsay K‐P Altidor, Ida Fredriksson, Aniruddha Shekara, Stephen Husbands, Agnieszka Sulima, Kenner C. Rice, Matthew L. Banks, Yavin Shaham. Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance. British Journal of Pharmacology 2022, 179 (2) , 227-241. https://doi.org/10.1111/bph.15679
    17. Anastasija O. Finke, Marina Y. Ravaeva, Vyacheslav I. Krasnov, Igor V. Cheretaev, Elena N. Chuyan, Dmitry S. Baev, Elvira E. Shults. Cross‐Coupling‐Cyclocondensation Reaction Sequence to Access a Library of Ring‐C Bridged Pyrimidino‐tetrahydrothebaines and Pyrimidinotetrahydrooripavines. ChemistrySelect 2021, 6 (29) , 7391-7397. https://doi.org/10.1002/slct.202101790
    18. Sylvain Auvity, Sébastien Goutal, Fabien Caillé, Dominique Vodovar, Alain Pruvost, Catriona Wimberley, Claire Leroy, Matteo Tonietto, Michel Bottlaender, Nicolas Tournier. Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. Neuropsychopharmacology 2021, 46 (6) , 1220-1228. https://doi.org/10.1038/s41386-021-00976-w
    19. Michael E. Meyer, Arpit Doshi, Dennis Yasuda, Nurulain T. Zaveri. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists. The AAPS Journal 2021, 23 (3) https://doi.org/10.1208/s12248-021-00589-7
    20. Huiping Ding, Mei-Chuan Ko. Translational value of non-human primates in opioid research. Experimental Neurology 2021, 338 , 113602. https://doi.org/10.1016/j.expneurol.2021.113602
    21. Norikazu Kiguchi, Huiping Ding, Shiroh Kishioka, Mei-Chuan Ko. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics. Current Topics in Medicinal Chemistry 2020, 20 (31) , 2878-2888. https://doi.org/10.2174/1568026620666200508082615
    22. Jasmin Krüll, Stefanie K. Fehler, Laura Hofmann, Natascha Nebel, Simone Maschauer, Olaf Prante, Peter Gmeiner, Harald Lanig, Harald Hübner, Markus R. Heinrich. Synthesis, Radiosynthesis and Biological Evaluation of Buprenorphine‐Derived Phenylazocarboxamides as Novel μ‐Opioid Receptor Ligands. ChemMedChem 2020, 15 (13) , 1175-1186. https://doi.org/10.1002/cmdc.202000180
    23. Paul Cumming, János Marton, Tuomas O. Lilius, Dag Erlend Olberg, Axel Rominger. A Survey of Molecular Imaging of Opioid Receptors. Molecules 2019, 24 (22) , 4190. https://doi.org/10.3390/molecules24224190
    24. Shawn M. Flynn, Phillip M. Epperly, April T. Davenport, Gerta Cami-Kobeci, Stephen M. Husbands, Mei-Chuan Ko, Paul W. Czoty. Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. Neuropsychopharmacology 2019, 44 (8) , 1476-1484. https://doi.org/10.1038/s41386-019-0390-z
    25. Norikazu Kiguchi, Huiping Ding, Gerta Cami-Kobeci, Devki D. Sukhtankar, Paul W. Czoty, Heather B. DeLoid, Fang-Chi Hsu, Lawrence Toll, Stephen M. Husbands, Mei-Chuan Ko. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. British Journal of Anaesthesia 2019, 122 (6) , e146-e156. https://doi.org/10.1016/j.bja.2018.10.065
    26. Christopher W. Cunningham, Waleed M. Elballa, Stephanie U. Vold. Bifunctional opioid receptor ligands as novel analgesics. Neuropharmacology 2019, 151 , 195-207. https://doi.org/10.1016/j.neuropharm.2019.03.006
    27. Nurulain T. Zaveri, Michael E. Meyer. NOP-Targeted Nonpeptide Ligands. 2019, 37-67. https://doi.org/10.1007/164_2019_213
    28. Jean M. Bidlack, Brian I. Knapp, Daniel R. Deaver, Margarita Plotnikava, Derrick Arnelle, Angela M. Wonsey, May Fern Toh, Sokhom S. Pin, Mark N. Namchuk. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder. Journal of Pharmacology and Experimental Therapeutics 2018, 367 (2) , 267-281. https://doi.org/10.1124/jpet.118.249839
    29. Vinod Kumar, Willma E. Polgar, Gerta Cami-Kobeci, Mark P. Thomas, Taline V. Khroyan, Lawrence Toll, Stephen M. Husbands. Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile. Frontiers in Psychiatry 2018, 9 https://doi.org/10.3389/fpsyt.2018.00430
    30. Jessica P. Anand, Deanna Montgomery. Multifunctional Opioid Ligands. 2018, 21-51. https://doi.org/10.1007/164_2018_104
    31. Huiping Ding, Paul W. Czoty, Norikazu Kiguchi, Gerta Cami-Kobeci, Devki D. Sukhtankar, Michael A. Nader, Stephen M. Husbands, Mei-Chuan Ko. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proceedings of the National Academy of Sciences 2016, 113 (37) https://doi.org/10.1073/pnas.1605295113
    32. Eduardo R. Butelman, Mary Jeanne Kreek. Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions. 2016, 175-192. https://doi.org/10.1007/7854_2016_9
    33. Marta Zielińska, Tanila Ben Haddou, Gerta Cami-Kobeci, Maciej Sałaga, Agata Jarmuż, Milena Padysz, Radzisław Kordek, Mariana Spetea, Stephen M. Husbands, Jakub Fichna. Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. European Journal of Pharmacology 2015, 765 , 582-590. https://doi.org/10.1016/j.ejphar.2015.09.021
    34. T V Khroyan, J Wu, W E Polgar, G Cami‐Kobeci, N Fotaki, S M Husbands, L Toll. BU 08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice. British Journal of Pharmacology 2015, 172 (2) , 668-680. https://doi.org/10.1111/bph.12796
    35. Marta Sobczak, Gerta Cami-Kobeci, Maciej Sałaga, Stephen M. Husbands, Jakub Fichna. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. European Journal of Pharmacology 2014, 736 , 63-69. https://doi.org/10.1016/j.ejphar.2014.04.038
    36. Richard J. Bodnar. Endogenous opiates and behavior: 2011. Peptides 2012, 38 (2) , 463-522. https://doi.org/10.1016/j.peptides.2012.09.027
    37. Colette M. Cremeans, Erin Gruley, Donald J. Kyle, Mei-Chuan Ko. Roles of μ-Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates. Journal of Pharmacology and Experimental Therapeutics 2012, 343 (1) , 72-81. https://doi.org/10.1124/jpet.112.194308

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    MENDELEY PAIRING EXPIRED
    Your Mendeley pairing has expired. Please reconnect